Table 1.
Summary of the expression, regulation, and functions of miR-205 in different cancers.
| Cancer type | miR-205 Expression | Regulatory mechanisms | Functions | Target genes | References |
|---|---|---|---|---|---|
| Prostate cancer | Downregulated | TFs (p63/ΔNp63α, HIF-1α), hypermetilation, deacetylation | Tumor-suppressor | N-chimerin, E2F1, E2F5, ZEB2, protein kinase Cε, MED1, MAPK, AR | 13,20,21,37,39,40,45,48 |
| Breast cancer | Downregulated (TNBC) | TF (p53), hypermetilation, deacetylation, lncRNA (linc-ROR) | Tumor-suppressor, oncogene | ZEB1, ZEB2, PTEN, HER3, VEGFA, FGF2 | 8,11,22,23,38,65 |
| Lung cancer | Downregulated (adenocarcinoma) or upregulated (squamous cell carcinoma) | Hypermethylation, deacetylation | Tumor-suppressor or oncogene; biomarker | PTEN, PHLPP2, RUNX1 | 35,41,51 |
| Renal cancer | Downregulated | lncRNA (LINC00152) | Tumor-suppressor | Src-family members, Ras/Raf/ERK1/2 | 25,66 |
| Head and neck cancer | Upregulated | TF (p53) | Oncogene, prognostic marker | PTEN | 30 |
| Melanoma | Downregulated | TFs (p73/ΔNp73) | Tumor-suppressor | E2F1, BCL2, VEGF | 24 |
| Bladder cancer | Downregulated invasive bladder cancer) or upregulated (non-invasive bladder cancer) | TF (ΔNp63α, Twist1), hypermetilation, lncRNA (HOTAIR) | Tumor-suppressor or oncogene | ZEB1, ZEB2 | 36,47,67 |
| Endometrial cancer | Upregulated | lncRNAs (RP11–395G23.3 and LA16c-313D11.11) | Oncogene, prognostic marker | PTEN, ESRRG | 26,27 |